Non-small cell lung cancer
Conditions
Interventions
experimental group:SHR-1210+Famitinib
Sponsors
Chinese Academy of Medical Sciences Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Participate voluntarily and sign the informed consent in writing; 2. Aged from 18 to 80 years, no gender limit; 3. Histologically or cytologically diagnosed as advanced NSCLC, first-line treatment failed, according to the solid tumor remission evaluation criteria (RECIST1.1), imaging diagnosis has at least one measurable lesion; 4. The expected survival period is >= 3 months; 5. ECOG score 0-1 points; 6. Sufficient organ and bone marrow function; 7. It is expected to have good compliance and be able to cooperate with the research according to the requirements of the plan.
Exclusion criteria
Exclusion criteria: 1. Have received any other systemic treatment after first-line progression; 2. Past or current idiopathic pulmonary fibrosis, interstitial pneumonia, or CT showing active pneumonia during the screening period; 3. Known to be allergic to research drugs and similar biological agents or any of their excipients; 4. Receive live attenuated vaccines within 4 weeks before the first dose or plan to receive live attenuated vaccines during the study period; 5. Immune suppressive drugs have been used within 14 days before the first use of Carrelizumab; 6. There is any active autoimmune disease or a history of autoimmune disease; 7. Suffer from myocardial ischemia or myocardial infarction above grade II, or poorly controlled arrhythmia; 8. Those who have a history of psychotropic drug abuse and cannot be quit or have mental disorders; 9. Have received major surgery within 4 weeks before the first dose; 10. The investigator judged that it is not suitable to participate in other situations in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival;Disease Control Rate;Duration of remission;Overall Survival; | — |
Countries
China
Contacts
Public ContactLiu Yutao
Chinese Academy of Medical Sciences Cancer Hospital
Outcome results
None listed